Module

Modifying Antiretroviral Therapy to Manage or Prevent Adverse Effects

Source: Fine-Tuning Antiretroviral Therapy in HIV-Infected Patients With Virologic Suppression: Strategies to Address Toxicity, Convenience, and Quality of Life

Modifying Antiretroviral Therapy to Manage or Prevent Adverse Effects

CME Program Director: John P. Phair, MD

Faculty:

Edwin DeJesus, MD, FACP, AAHIVS

CME CREDIT INFORMATION

Release Date: 11/14/06

Expiration Date: 11/13/07

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.4 Nursing CE credits

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Identify toxicities associated with antiretroviral therapy
Describe antiretroviral switch strategies designed to improve the tolerability of a virologically suppressive regimen
Discuss the results of clinical trials evaluating switches in antiretroviral therapy in patients with virologic suppression

Topics covered include:

Introduction
Overview of Antiretroviral-Associated Toxicities
Overview of Switch Studies Designed to Manage or Prevent Antiretroviral Toxicities
Switching to Manage Lipoatrophy
Switching to Manage Dyslipidemia
Switching to Manage Anemia
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.